A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

NCT02766699 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Astrocytoma, Grade IV

Interventions

DRUG: EGFR(V)-EDV-Dox

Sponsor

Engeneic Pty Limited

Collaborators

[object Object]